The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
Innate to receive $5M milestone payment from AstraZeneca
It is developing the drug candidate to potentially treat immunological diseases
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains in older and younger adults, even at lowest dose; no significant safety concerns were observed
Subscribe To Our Newsletter & Stay Updated
